Immune Checkpoint Inhibitors: all 7,814 studies that test it

Page 51 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.

• Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCCStatus unknownNCT05469061Phase 2
• PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical SurgeryActive, not recruitingNCT05468138Phase 2
• Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent GlioblastomaActive, not recruitingNCT05465954Phase 2
• Surgical Pembro +/- Olaparib w TMZ for rGBMActive, not recruitingNCT05463848Phase 2
• Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 InhibitorsStatus unknownNCT05460481Phase 2
• Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutantWithdrawnNCT05457959Phase 1
• Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell LymphomaActive, not recruitingNCT05455697Phase 1/2
• Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid CancerSuspendedNCT05453799Phase 2
• Clinical Recruitment of Patients With First-line Targeted Drug Resistance or Intolerance to Hepatocellular Cancer With PD-1 Inhibitor (Toripalimab,JS001) Detected on the NGS Platform Combined With AnlotinibStatus unknownNCT05453383Phase 2
• Efficacy and Safety of TQB2618 Injection Combined With Toripalimab Injection in Patients With Advanced MelanomaStatus unknownNCT05451407Phase 1
• Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract CancerActive, not recruitingNCT05451290Phase 2
• A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based ChemotherapyActive, not recruitingNCT05450692Phase 3
• YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic SarcomaActive, not recruitingNCT05448820Phase 1/2
• A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDSStatus unknownNCT05448599Phase 1/2
• An Observational Real World Study on the Efficacy and Safety of Toripalimab Injection Combined With TACE in the Treatment of Extrahepatic CholangiocarcinomaStatus unknownNCT05448183Phase 2
• A Clinical Study of 6MW3211 Injection in the Treatment of Relapsed/Refractory LymphomaStatus unknownNCT05446688Phase 2
• ONC-392 and Pembrolizumab in Platinum Resistant Ovarian CancerActive, not recruitingNCT05446298Phase 2
• Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate CancerSuspendedNCT05445609Phase 2
• Durvalumab and Grid Therapy for Non-small Cell Lung Cancer in Progression During or After Treatment With PACIFIC RegimenTerminatedNCT05443971Phase 1
• Camrelizumab Combined With Intraperitoneal Infusion of Nab-paclitaxel, Intravenous Chemotherapy and S-1 in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis：Single-arm, Prospective Clinical StudyStatus unknownNCT05441254Phase 2
• Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid TumorsStatus unknownNCT05441046Phase 1
• Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal AdenocarcinomaCompletedNCT05440942Phase 1
• A Safety Study of LY3462817 in Healthy Japanese and Non-Japanese ParticipantsCompletedNCT05440136Phase 1
• A Clinical Study of 6MW3211 in Patients With Renal CancerStatus unknownNCT05440045Phase 2
• Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point InhibitorTerminatedNCT05436990Phase 2
• Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard TherapyActive, not recruitingNCT05435313Phase 2
• Irreversible Electroporation + Nivolumab for Patients With Metastatic Pancreatic CancerTerminatedNCT05435053Phase 2
• A Study of AK112 in Patients With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT05432492Phase 2
• A Phase IIa Study to Evaluate the Efficacy and Safety of 6MW3211 in Patients With Advanced Lung CancerStatus unknownNCT05431569Phase 2
• Immunological Variables Associated to ICI Toxicity in Cancer PatientsStatus unknownNCT05429866Phase 2
• Precise Therapy for Refractory HER2 Positive Advanced Breast CancerStatus unknownNCT05429684Phase 3
• A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid TumorsTerminatedNCT05427396Phase 1
• Clinical Study of TQB2618 Injection in Combination With Demethylation Drugs in Patients With Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic SyndromesStatus unknownNCT05426798Phase 1
• Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal CancerActive, not recruitingNCT05426005Phase 1/2
• Study of KN046 in Subjects With Advanced Non-Small Cell Lung CancerCompletedNCT05420220Phase 2
• Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair SystemWithdrawnNCT05419817Phase 2
• A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic MelanomaCompletedNCT05419388Phase 2
• A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous MelanomaActive, not recruitingNCT05418972Phase 2
• Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable: a Multi-center StudyStatus unknownNCT05418309Phase 2
• Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic CancerActive, not recruitingNCT05411094Phase 1
• Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 TrialActive, not recruitingNCT05411081Phase 2
• Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def TumorsActive, not recruitingNCT05407441Phase 1/2
• Pembrolizumab in Muscle-invasive Bladder CancerActive, not recruitingNCT05406713Phase 2
• Cryoablation Combined With Tislelizumab Plus Lenvatinib in Patients With Melanoma Liver MetastasisStatus unknownNCT05406466Phase 2
• Dostarlimab in Chemoresistant Gestational Trophoblastic NeoplasiaWithdrawnNCT05405192Phase 2
• Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and AboveActive, not recruitingNCT05404945Phase 2
• Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLCSuspendedNCT05403723Phase 1
• A Study of NI-1801 in Patients with Mesothelin Expressing Solid CancersStatus unknownNCT05403554Phase 1
• Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast CancerStatus unknownNCT05402722Phase 2
• Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLCActive, not recruitingNCT05401786Phase 2
• To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Penpulimab in the Treatment of Patients With Relapsed and Refractory LymphomaStatus unknownNCT05400876Phase 1/2
• Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid TumorCompletedNCT05400265Phase 1
• Clinical Study of Regorafenib and Nivolumab Plus ChemotherapyCompletedNCT05394740Phase 1/2
• Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial CarcinomaActive, not recruitingNCT05394337Phase 1/2
• Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 StudyTerminatedNCT05393713Phase 1
• Fedratinib in Combination With NivolumabCompletedNCT05393674Phase 2
• A Study to Evaluate the Efficacy and Safety of AK127 in Patients With Advanced Solid TumorsStatus unknownNCT05393063Phase 1
• A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or LymphomaStatus unknownNCT05390528Phase 1/2
• Pembrolizumab and Lenvatinib for Resectable Hepatocellular CarcinomaActive, not recruitingNCT05389527Phase 2
• Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaActive, not recruitingNCT05388006Phase 2
• Sintilimab and Bevacizumab Biosimilar Combined With PLD in mTNBCStatus unknownNCT05386524Phase 2
• Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell CarcinomaStatus unknownNCT05386056Phase 2
• Addition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at LymphodepletionStatus unknownNCT05385263Phase 2
• Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung CancerActive, not recruitingNCT05384015Phase 2
• Neoadjuvant/Adjuvant Pembrolizumab Plus ChemotherapyActive, not recruitingNCT05383716Phase 2
• A Study of AK112 With or Without AK117 in Metastatic Colorectal CancerActive, not recruitingNCT05382442Phase 2
• Study of AGEN1571 in Participants With Advanced Solid TumorsCompletedNCT05377528Phase 1
• A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)CompletedNCT05375903Phase 1
• SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS MutationTerminatedNCT05375084Phase 1
• Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLCActive, not recruitingNCT05374603Phase 2
• Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal CancerStatus unknownNCT05371197Phase 2
• Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type PatientCompletedNCT05368207Not applicable
• A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS ParticipantsWithdrawnNCT05367401Phase 1/2
• Pembrolizumab Plus Olaparib in LA-HNSCCActive, not recruitingNCT05366166Phase 2
• BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer PatientsWithdrawnNCT05363709Phase 2
• Seleno-L Methionine (SLM)-Axitinib-PembrolizumabActive, not recruitingNCT05363631Phase 1/2
• IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint InhibitorActive, not recruitingNCT05359445Phase 1
• A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung CancerStatus unknownNCT05354700Phase 2
• Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung CancerActive, not recruitingNCT05353439Phase 1
• A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung CancerActive, not recruitingNCT05353257Phase 3
• Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline TherapyActive, not recruitingNCT05352828Phase 1
• Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic MelanomaActive, not recruitingNCT05352672Phase 3
• HAIC Combined With Toripalimab and Donafenib for Advanced BTCStatus unknownNCT05350943Phase 2
• Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal MedullaActive, not recruitingNCT05347212Phase 2
• A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC).Status unknownNCT05346952Phase 3
• Efficacy of VTP-300 in Chronic Hepatitis B InfectionCompletedNCT05343481Phase 2
• The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advanced HNSCCActive, not recruitingNCT05343325Phase 2
• A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)CompletedNCT05342636Phase 1/2
• Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric CancerStatus unknownNCT05342389Phase 2
• Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain MetastasesTerminatedNCT05341349Phase 1
• Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung CancerActive, not recruitingNCT05340309Phase 2
• A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors.Status unknownNCT05338957Phase 1/2
• A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05338775Phase 1
• A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare CancersSuspendedNCT05337735Phase 2
• Phase I Study of Sintilimab in Healthy Chinese Male SubjectsCompletedNCT05337267Phase 1
• A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial CarcinomaActive, not recruitingNCT05335941Phase 2
• To Determine the Efficacy and Safety of Envafolimab Combined With XELOX for Locally Advanced Colon CancerStatus unknownNCT05335460Phase 2
• Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint InhibitorsActive, not recruitingNCT05334329Phase 1
• Clinical Trial of the TQB3602 Capsule Combined With AK105 Injection in Patients With Advanced CancersActive, not recruitingNCT05333276Phase 1
• Safety, Tolerability, PK, PD and Preliminary Efficacy of ONO-4685CompletedNCT05332704Phase 1

← Immune Checkpoint Inhibitors overview